Genentech Inc (DNA) will likely reject Roche Holding AG’s $42 billion bid, since it considers the $86.50 per share buyout offer as substantially undervaluing the company. Roche, after the U.S. biotech group urged shareholders to reject the offer, has said that Genentech’s banker, Goldman Sachs (GS), had proposed $112 a share as an acceptable price.
| INDU | 0.00 | |||||||
| NASDAQ | 2927.23 | |||||||
| S&P 500 | 1351.95 | |||||||
| DJIA Fut | 12842.00 | |||||||
| Nasdaq Fut | 2558.75 | |||||||
| S&P Fut | 1346.10 | |||||||
| Oil Fut | 97.12 | |||||||
| Gold Fut | 1731.80 | |||||||
| Nikkei | 8980.49 | |||||||
| Shanghai | 2349.589 | |||||||
| UK | 5895.47 | |||||||
| France | 3424.71 | |||||||
| Germany | 6788.80 | |||||||
-
Blog Roll
-
Blog Roll (Random)
